Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology

Peter Seferović^{1

2}, Dimitrios Farmakis³, Antoni Bayes-Genis^{4

5

6}, Tuvia Ben Gal⁷, Michael Böhm⁸, Ovidiu Chioncel⁹, Roberto Ferrari^{10

11}, Gerasimos Filippatos¹², Loreena Hill¹³, Ewa Jankowska^{14

15}, Mitja Lainscak¹⁶, Yuri Lopatin¹⁷, Lars H Lund¹⁸, Alexandre Mebazaa¹⁹, Marco Metra²⁰, Brenda Moura²¹, Giuseppe Rosano^{22

23}, Thomas Thum^{24

25

26}, Adriaan Voors²⁷, Andrew J S Coats²⁸

Affiliations

¹ Faculty of Medicine, University of Belgrade Belgrade, Serbia and Serbian Academy of Sciences and Arts, Belgrade, Serbia.
² University of Belgrade Belgrade, Belgrade, Serbia.
³ University of Cyprus Medical School, Nicosia, Cyprus.
⁴ Heart Institute, Hospital Universitari German Trias i Pujol, Badalona, Spain.
⁵ Department of Medicine, Universitat Autónoma de Barcelona, Barcelona, Spain.
⁶ CIBERCV, Instituto de Salud, Madrid, Spain.
⁷ Heart Failure Unit, Cardiology Department, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁸ Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany.
⁹ Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, and University of Medicine Carol Davila, Bucharest, Romania.
¹⁰ Maria Cecilia Hospital, GVM Care & Research, Ravenna, Italy.
¹¹ Laboratory for Technologies of Advanced Therapies (LTTA), Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
¹² Second Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrina University of Athens Medical School, Athens, Greece.
¹³ School of Nursing and Midwifery, Queen's University, Belfast, UK.
¹⁴ Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
¹⁵ Centre for Heart Diseases, University Hospital, Wroclaw, Poland.
¹⁶ Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
¹⁷ Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russian Federation.
¹⁸ Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
¹⁹ INSERM UMR-S 942, Paris, France; Department of Anesthesiology and Critical Care Medicine, St. Louis and Lariboisère University Hospitals, Paris, France.
²⁰ Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
²¹ CINTESIS - Centro de Investigação em Tecnologias e Serviços de Saúde, Porto, Portugal; Serviço de Cardiologia, Hospital das Forças Armadas - Pólo do Porto, Porto, Portugal.
²² Cardiovascular Clinical Academic Group, St George's Hospitals NHS Trust University of London, London, UK.
²³ IRCCS San Raffaele Pisana, Rome, Italy.
²⁴ Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
²⁵ REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.
²⁶ Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.
²⁷ Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
²⁸ Warwick Medical School, University of Warwick, Coventry, UK.

PMID: 35703329
DOI: 10.1002/ejhf.2575

Free article

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology

Peter Seferović et al. Eur J Heart Fail. 2022 Jul.

Free article

. 2022 Jul;24(7):1162-1170.

doi: 10.1002/ejhf.2575. Epub 2022 Jul 5.

Authors

Affiliations

¹ Faculty of Medicine, University of Belgrade Belgrade, Serbia and Serbian Academy of Sciences and Arts, Belgrade, Serbia.
² University of Belgrade Belgrade, Belgrade, Serbia.
³ University of Cyprus Medical School, Nicosia, Cyprus.
⁴ Heart Institute, Hospital Universitari German Trias i Pujol, Badalona, Spain.
⁵ Department of Medicine, Universitat Autónoma de Barcelona, Barcelona, Spain.
⁶ CIBERCV, Instituto de Salud, Madrid, Spain.
⁷ Heart Failure Unit, Cardiology Department, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁸ Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany.
⁹ Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, and University of Medicine Carol Davila, Bucharest, Romania.
¹⁰ Maria Cecilia Hospital, GVM Care & Research, Ravenna, Italy.
¹¹ Laboratory for Technologies of Advanced Therapies (LTTA), Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
¹² Second Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrina University of Athens Medical School, Athens, Greece.
¹³ School of Nursing and Midwifery, Queen's University, Belfast, UK.
¹⁴ Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
¹⁵ Centre for Heart Diseases, University Hospital, Wroclaw, Poland.
¹⁶ Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
¹⁷ Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russian Federation.
¹⁸ Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
¹⁹ INSERM UMR-S 942, Paris, France; Department of Anesthesiology and Critical Care Medicine, St. Louis and Lariboisère University Hospitals, Paris, France.
²⁰ Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
²¹ CINTESIS - Centro de Investigação em Tecnologias e Serviços de Saúde, Porto, Portugal; Serviço de Cardiologia, Hospital das Forças Armadas - Pólo do Porto, Porto, Portugal.
²² Cardiovascular Clinical Academic Group, St George's Hospitals NHS Trust University of London, London, UK.
²³ IRCCS San Raffaele Pisana, Rome, Italy.
²⁴ Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
²⁵ REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.
²⁶ Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.
²⁷ Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
²⁸ Warwick Medical School, University of Warwick, Coventry, UK.

PMID: 35703329
DOI: 10.1002/ejhf.2575

Erratum in

Corrigendum to: 'A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry' and articles listed below.
[No authors listed] [No authors listed] Eur J Heart Fail. 2023 Mar;25(3):443. doi: 10.1002/ejhf.2789. Epub 2023 Feb 17. Eur J Heart Fail. 2023. PMID: 36799232 Free PMC article. No abstract available.

Abstract

Knowledge on risk predictors of incident heart failure (HF) in patients with type 2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognized as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established cardiovascular biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and cardiovascular events in patients with T2D and in those with established HF and T2D.

Keywords: Biomarkers; Cardiovascular prevention; Cardiovascular risk; Diabetes mellitus; Heart failure.

PubMed Disclaimer

References

1. Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:853-72.
1. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39:4243-54.
1. Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, et al. Heart failure end points in cardiovascular outcome trials of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a critical evaluation of clinical and regulatory issues. Circulation. 2019;140:2108-18.
1. Farmakis D, Butler J, Filippatos G. Sodium-glucose co-transporter 2 inhibitors: ‘a tale of two sisters’, diabetes and heart failure. Eur J Heart Fail. 2020;22:1259-62.
1. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al.; ESC-HFA HF Long-Term Registry Investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:54-65.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology

Affiliations

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology

Authors

Affiliations

Erratum in

Abstract

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous